GSK
FDA Approves GSK's Jemperli With Ventana CDx for dMMR Endometrial Cancer
The FDA also approved the Ventana MMR RxDx panel as a companion diagnostic to select endometrial cancer patients for treatment with dostarlimab.
CHMP Recommends Approval of GSK's Dostarlimab in Endometrial Cancer
The CHMP opinion is based on data from a Phase I/II study of dostarlimab in mismatch repair-deficient or microsatellite instability-high endometrial cancer.
FDA Accepts Ideaya Biosciences' IND for MAT2A Inhibitor
Ideaya will now begin a Phase I trial evaluating its MAT2A inhibitor, IDE397, in solid cancers with MTAP gene deletions.
Merck KGaA Discontinues Phase III Lung Cancer Trial of Bintrafusp Alfa
A data safety monitoring committee said the trial, exploring the first-line activity of bintrafusp against Keytruda in PD-L1-high, advanced NSCLC, wouldn't meet its primary endpoint.
JP Morgan Healthcare, Day 2: Eli Lilly, Pfizer, GlaxoSmithKline, Clovis Oncology, Invitae, and More
Verzenio, Ibrance, Rubraca, and bintrafusp alfa are some of the precision oncology products companies provided updates on during the conference. Â